ReviewCurrent opinion in neurobiology2015
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice.
Review in Current opinion in neurobiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04260607 (Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department), which is not on this map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department
Who cites it
73 citing papers in PubMed.
- Acetyl-l-carnitine deficiency in patients with major depressive disorder.Proceedings of the National Academy of Sciences of the United States of America · 2018Trial
- Bifunctional Modulation of NMDA and Opioid Receptors in Ketamine Reinforcement and Misuse: Implications for Substance Use Disorder Treatment.Biological psychiatry · 2026Review
- Circadian clock genes and insomnia: molecular mechanisms and therapeutic implications.Annals of medicine · 2025Review
- Ketamine in clinical practice: transitioning from anesthetic agent to psychiatric therapeutic.CNS spectrums · 2025Review
- Environmental determinants of ketamine's prohedonic and antianhedonic efficacy: Persistence of enhanced reward responsiveness is modulated by chronic stress.The Journal of pharmacology and experimental therapeutics · 2025Article
- Ketamine in Substance Use Disorder Treatment: A Narrative Review.Alpha psychiatry · 2024Review
- Ketamine in neuropsychiatric disorders: an update.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Article
- Non-sedative cortical EEG signatures of allopregnanolone and functional comparators.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Article
- A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical Antipsychotics.Neuropsychiatric disease and treatment · 2023Article
- Potential of Heterogeneous Compounds as Antidepressants: A Narrative Review.International journal of molecular sciences · 2022Review
- Effects of stress on endophenotypes of suicide across species: A role for ketamine in risk mitigation.Neurobiology of stress · 2022Review
- Effects of subanesthetic ketamine and (2R,6R) hydroxynorketamine on working memory and synaptic transmission in the nucleus reuniens in mice.Neuropharmacology · 2022Article
- Convergence of Clinically Relevant Manipulations on Dopamine-Regulated Prefrontal Activity Underlying Stress Coping Responses.Biological psychiatry · 2022Article
- A New Player in Depression: MiRNAs as Modulators of Altered Synaptic Plasticity.International journal of molecular sciences · 2022Review
- Factors Influencing Perceived Helpfulness and Participation in Innovative Research: A Pilot Study of Individuals with and without Mood Symptoms.Ethics & behavior · 2022Article
- Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression.Psychopharmacology · 2021Article
- Frontal cortex genetic ablation of metabotropic glutamate receptor subtype 3 (mGluNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Article
- The Sustained Antidepressant Effects of Ketamine Are Independent of the Lateral Habenula.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021Article
- Biomarkers of Major Depressive Disorder: Knowing is Half the Battle.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2021Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In the past decade the emergence of glutamate N-methyl-d-aspartate (NMDA) receptor blockers such as ketamine as fast-acting antidepressants fostered a major conceptual advance by demonstrating the possibility of a rapid antidepressant response. This discovery brings unique mechanistic insight into antidepressant action, as there is a substantial amount of basic knowledge on glutamatergic neurotransmission and how blockade of NMDA receptors may elicit plasticity. The combination of this basic knowledge base and the growing clinical findings will facilitate the development of novel fast acting antidepressants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.